During the last decade, monoclonal antibodies targeting CD38 (daratumumab, isatuximab) have improved patient outcomes significantly, and they have been incorporated into the therapeutic algorithm of MM both for newly diagnosed patients and in the relapsed/refractory setting [11]. The gene discussed is CD38; the disease is Miyoshi myopathy.